Navigation Links
EntreMed Receives Notice of NASDAQ Compliance
Date:10/15/2010

statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Contact:Ginny DunnAssociate DirectorCorporate Communications & Investor Relations240-864-2643
'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The Eastern European medical device ... providers as well as new medical-device manufacturers are constantly ... looking at ways to reduce the cost incurred for ... one of the effective means to achieve this target. ... in Eastern European and provides profiles of key distributors ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
(Date:9/30/2014)... , September 30, 2014 In ... CSF (Cerebrospinal Fluid) backflow of the Eldor spinal needle ... the single hole pencil point spinal needles of the ... Spinal anesthesia is an excellent type of ... Urology, General Anesthesia, etc. It is estimated ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... DIEGO, March 24 Calixa Therapeutics Inc. today announced ... CXA-101, a novel cephalosporin antibiotic with excellent in ... Phase 1 study demonstrated that CXA-101 was well tolerated, ... that of marketed cephalosporin antibiotics. No dose-limiting toxicity was ...
... ClinicROCHESTER, Minn., March 23 Here are highlights ... Clinic,s research magazine. You may cite and link ... Reprinting is allowed with proper attribution. Please include ... permit: Visit http://discoverysedge.mayo.edu for subscription information.Parkinsonism: ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:9/30/2014)... A new study of 58 women conducted ... stress on metabolism after eating a high-fat meal equivalent to ... food restaurant, about 930 calories and 60 grams of fat. ... hour for 7 hours, conducting the study twice on each ... a stressful event in their lives during the previous 24 ...
(Date:9/30/2014)... 2014(BRONX, NY)Medications are the leading cause of allergy-related sudden ... death certificates from 1999 to 2010, conducted by researchers ... Albert Einstein College of Medicine of Yeshiva University . ... of Allergy and Clinical Immunology , also found that ... high among older people and African-Americans and that such ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... small Gram-negative spiral rods. Campylobacter jejuni ( ... water, milk and meat, especially chicken, is one of ... its mode of pathogenesis is not clear. , A ... in the World Journal of Gastroenterology addresses ...
... China Medical Technologies,Inc. (the "Company") (Nasdaq: ... device,company that develops, manufactures and markets advanced ... has completed the previously,announced sale of its ... (the "HIFU Business") to Chengxuan International Ltd. ...
... 30 Cardium Therapeutics,(NYSE Alternext US: CXM) reported ... indicating that the company is currently considered to ... Alternext US LLC,(formerly the American Stock Exchange). ... which was filed on November 10, 2008, noncompliance ...
... CAMBRIDGE, Mass., Dec. 30 Biopure Corporation (Nasdaq: ... has advised the U.S. Naval Medical Research Center ("NMRC") by ... Biopure,s product Hemopure [hemoglobin glutamer - 250 (bovine)], under a ... As previously announced, the Navy had filed a protocol ...
... repair genes initially appeared to be statistically significantly associated ... from individual studies are pooled, however, few DNA repair ... according to a field synopsis published in the December ... National Cancer Institute. , Because DNA damage is ...
... WLP ) will,release fourth quarter 2008 financial results ... Management will review these results and its,outlook during a conference ... should be accessed at least 15 minutes prior to its ... (Domestic) ...
Cached Medicine News:Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 2Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 3Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 4Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 5Health News:U.S. Navy Requested Operations Trial on FDA Hold 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 3Health News:Few DNA repair genes maintain association with cancer in field synopsis 2Health News:WellPoint to Hold Conference Call and Webcast to Discuss Fourth Quarter Results on January 28, 2009 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: